Search

Your search keyword '"Cooper-Knock, Johnathan"' showing total 223 results

Search Constraints

Start Over You searched for: Author "Cooper-Knock, Johnathan" Remove constraint Author: "Cooper-Knock, Johnathan" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
223 results on '"Cooper-Knock, Johnathan"'

Search Results

2. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

3. Rare and common genetic determinants of mitochondrial function determine severity but not risk of amyotrophic lateral sclerosis

4. Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis

5. Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS

6. Rare and common genetic determinants of mitochondrial function determine severity but not risk of amyotrophic lateral sclerosis

7. Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS

8. Characterisation of genotype-phenotype relationships in ALS associated with hexanucleotide repeat expansion of C9orf72

10. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.

12. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

15. A Y374X TDP43 truncation leads to an altered metabolic profile in amyotrophic lateral sclerosis fibroblasts driven by pyruvate and TCA cycle intermediate alterations

17. Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival

18. Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival

19. Clinical testing panels for ALS : global distribution, consistency, and challenges

20. Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival

21. Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival

23. Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data

24. Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication

25. Multiomic analysis reveals cell-type-specific molecular determinants of COVID-19 severity

26. AtypicalTDP‐43 protein expression in anALSpedigree carrying a p.Y374Xtruncation mutation inTARDBP

27. Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis

28. Author Correction : Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

29. Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data

30. Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis

33. Unbiased metabolome screen leads to personalized medicine strategy for amyotrophic lateral sclerosis

34. Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis

35. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

36. Atypical TDP‐43 protein expression in an ALS pedigree carrying a p.Y374X truncation mutation in TARDBP.

37. Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication.

38. A review of Mendelian randomization in amyotrophic lateral sclerosis

39. Physical exercise is a risk factor for amyotrophic lateral sclerosis: Convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes

40. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

41. Advances in the genetic classification of amyotrophic lateral sclerosis

43. Microglia in Motor Neuron Disease

44. Rare variant burden analysis within enhancers identifies CAV1 as an ALS risk gene

45. Spatiotemporal Proteomic Analysis of Stress Granule Disassembly Using APEX Reveals Regulation by SUMOylation and Links to ALS Pathogenesis

46. Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene

47. A review of Mendelian randomization in amyotrophic lateral sclerosis.

49. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72

Catalog

Books, media, physical & digital resources